Fournet Alain auteur aut IRD Ferreira M.E. auteur aut IRD Rojas de Arias A. auteur aut IRD Torres de Ortiz S. auteur aut IRD Inchausti A. auteur aut IRD Yaluff G. auteur aut IRD Quilhot W. auteur aut IRD Fernandez E. auteur aut IRD Hidalgo M.E. auteur aut IRD text journalArticle eng text/pdf reformatted digital access Three secondary metabolites isolated from Chilean lichens, (+) usnic acid, pannarine and 1'-chloropannarine, were tested against promastigotes forms of three strains of Leishmania ssp. Pannarine and 1'-chloropannarine exhibited in vitro activity at 50 microg/ml and (+) usnic acid at 25 microg/ml. BALB/c mice infected with Leishmania amazonensis were treated 4 weeks post-infection with (+) usnic acid by subcutaneous or oral routes for 15 days at 25 mg/kg or by five intralesional injections at interval of 4 days at 25 mg/kg of body weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous injections (regimens of 28 mg of pentavalent antimony) for 15 days. The subcutaneous and oral treatments with (+) usnic did not produce any effect, but by intralesional administration we observed a significant effect that reduced by 43.34% the weight lesions and by 72.28% the parasites loads in infected footpads. (Résumé d'auteur) specialized LEISHMANIOSE TRAITEMENT MEDICAL EFFICACITE ETUDE EXPERIMENTALE PLANTE MEDICINALE EXTRACTION ANIMAL DE LABORATOIRE LICHEN ACIDE USNIQUE PANNARINE CHLOROPANNARINE 052PHLEIS03 076PLAMED03 116C 1 51-54 1997 0742-8413 https://www.documentation.ird.fr/hor/fdi:010009663 0742-8413 [F B010009663] https://www.documentation.ird.fr/hor/fdi:010009663 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_6/b_fdi_45-46/010009663.pdf IRD - Base Horizon / Pleins textes 1997-04-09 2021-05-27 fdi:010009663 fre